This is the first study that demonstrates the effects of a formulation containing a DPP-4 inhibitor together with a Flavonoid, both with antidiabetic properties, in promoting the improvement of metabolic homeostasis in a T1DM model. Here, DPP4 is linked to type 1 diabetes mellitus.